SNO 2019: The Oncolytic Herpes Virus G47? May Lead to a Potential Cure of Malignant Glioma
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is a small study and needs to be replicated but this might be the biggest advance we have ever seen. They reported a 1 year survival rate of 92% in recurrent glioblastoma. This is unheard of. Typically they expect 15% 1 year survival. The survival curve (compared to historical controls) is on our website at https://forum.virtualtrials.org/forum/brain-tumor-research/122-g47-delta-results-available-on-17thnovember and it is very impressive.
Unfortunately it appears as if this is only available in Japan. We need to get this to the USA.
The treatment is a third generation oncolytic herpes virus and it seems to work in all types of cancers that they tried. The clinical trial was terminated early because it actually works,
Posted on: 11/25/2019
Click HERE to return to brain tumor news headlines